Sitagliptin phosphate monohydrate
CAS: 654671-77-9
Ref. 3D-FS159000
| 10g | 168.00 € | ||
| 25g | 271.00 € | ||
| 50g | 406.00 € | ||
| 100g | 543.00 € | ||
| 250g | 723.00 € |
Product Information
- (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine dihydrogen phosphate monohydrate
- (3R)-3-amino-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one phosphate hydrate (1:1:1)
- 1,2,4-Triazolo[4,3-a]pyrazine, 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, phosphate (1:1), monohydrate
- 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, phosphate, hydrate (1:1:1)
- 7-[(3R)-3-Amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine phosphate monohydrate
- Sitagliptin Phosphate Monohydrate
- Sitagliptin phosephate monohydrate
- Sitagliptin phosphate hydrate
Sitagliptin phosphate monohydrate is a DPP-IV inhibitor that is used to treat type 2 diabetes mellitus. Sitagliptin decreases postprandial glucose levels and improves glycemic control. It binds to the enzyme DPP-IV, which breaks down peptides in the small intestine, inhibiting the breakdown of incretin hormones such as glucagon-like peptide 1 and glucose transporter type 2 (GLUT2). This leads to increased levels of GLP-1. Sitagliptin also has been shown to have an anti-diabetic effect by increasing insulin release from pancreatic beta cells.
Chemical properties
Technical inquiry about: 3D-FS159000 Sitagliptin phosphate monohydrate
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
